Kyu Young Rhee

Kyu Young Rhee

Auto-generated profile, based on publicly available information

Kyu Young Rhee

Department of Medicine, Weill Cornell Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
HEHyungjin Eoh
Hyungjin Eoh
KRKyu Y. Rhee
Kyu Y. Rhee
Mycobacterium tuberculosis is a chronic, facultative intracellular pathogen that spends the majority of its decades-long life cycle in a non- or slowly replicating state. However, the bacterium remains poised to resume replicating so that it can transmit itself to a new host. Knowledge of the metabolic adaptations used to facilitate entry into and exit from nonreplicative states remains incomplete. Here, we apply 13 C-based metabolomic profiling to characterize the activity of M. tuberculosis tricarboxylic acid cycle during adaptation to and recovery from hypoxia, a physiologically relevant condition associated with nonreplication. We show that, as M. tuberculosis adapts to hypoxia, it slows and remodels its tricarboxylic acid cycle to increase production of succinate, which is used to flexibly sustain membrane potential, ATP synthesis, and anaplerosis, in response to varying degrees of O 2 limitation and the presence or absence of the alternate electron acceptor nitrate. This remodeling is mediated by the bifunctional enzyme isocitrate lyase acting in a noncanonical role distinct from fatty acid catabolism. Isocitrate lyase-dependent production of succinate affords M. tuberculosis with a unique and bioenergetically efficient metabolic means of entry into and exit from hypoxia-induced quiescence.

24 April 2018 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
SESabine Ehrt
Sabine Ehrt
DSDirk Schnappinger
Dirk Schnappinger
KRKyu Y. Rhee
Kyu Y. Rhee

18 August 2021 in Nature
Verified
Journal Article
Closed access
PDF file
STSamuel R. Taylor
Samuel R. Taylor
SRShakti Ramsamooj
Shakti Ramsamooj
RLRoger J. Liang
Roger J. Liang
AKAlyna Katti
Alyna Katti
RPRita Pozovskiy
Rita Pozovskiy
MGMarcus Goncalves
Marcus Goncalves

20 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CGCandice R. Gurbatri
Candice R. Gurbatri
GRGeorgette A. Radford
Georgette A. Radford
LVLaura Vrbanac
Laura Vrbanac
JIJongwon Im
Jongwon Im
ETElaine M. Thomas
Elaine M. Thomas
TDTal Danino
Tal Danino
Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of colorectal adenomas after oral delivery of probiotic E. coli Nissle 1917 (EcN) to a genetically-engineered murine model of CRC predisposition and orthotopic models of CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which CRC patients take either placebo or EcN for two weeks prior to resection of neoplastic and adjacent normal colorectal tissue (ACTRN12619000210178). We detect enrichment of EcN in tumor samples over normal tissue from probiotic-treated patients (primary outcome of the trial). Next, we develop early CRC intervention strategies. To detect lesions, we engineer EcN to produce a small molecule, salicylate. Oral delivery of this strain results in increased levels of salicylate in the urine of adenoma-bearing mice, in comparison to healthy controls. To assess therapeutic potential, we engineer EcN to locally release a cytokine, GM-CSF, and blocking nanobodies against PD-L1 and CTLA-4 at the neoplastic site, and demonstrate that oral delivery of this strain reduces adenoma burden by ~50%. Together, these results support the use of EcN as an orally-deliverable platform to detect disease and treat CRC through the production of screening and therapeutic molecules.

17 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
HEHyungjin Eoh
Hyungjin Eoh
KRKyu Y. Rhee
Kyu Y. Rhee
Significance: Essentiality is a phenotypic trait of genes frequently used to identify new potential drug targets. However, genes function within the context of complex and extensively interconnected physiologic networks, making it difficult to discern the specific mechanisms responsible for their essentiality. Here, we apply a combination of chemogenetic and metabolomic approaches to resolve the specific biochemical mechanism associated with the bactericidal essentiality of the metabolic enzyme, isocitrate lyase (ICL), for survival of Mycobacterium tuberculosis (Mtb), a chronic intracellular pathogen, on fatty acids, a major carbon source thought to be encountered in vivo. These studies not only provide a systems level insight into the essentiality of Mtb’s ICL but also reveal a previously unrecognized link between propionate metabolism and membrane bioenergetics.

4 January 2013 in Science
Verified
Journal Article
Closed access
PDF file
SCSumit Chakraborty
Sumit Chakraborty
TGTodd Gruber
Todd Gruber
CIClifton Earl Barry, III
Clifton Earl Barry, III
HBHelena I. Boshoff
Helena I. Boshoff
KRKyu Y. Rhee
Kyu Y. Rhee
Poisoned Pathways: Fifty years ago, para -aminosalicyclic acid (PAS) was developed as an antituberculosis drug. Since then, it has been assumed that PAS acts to competitively inhibit para -aminobenzoate (PABA) from entering the folate pathway at the enzyme dihydropteroate synthase (DHPS). Strangely, the well-known inhibitors of DHPS—the sulfonamide drugs—are useless in tuberculosis treatment, although they are effective against other microbial pathogens. Chakraborty et al. (p. 88 , published online 1 November) addressed this conundrum by comparing the effect of several sulfonamides, as well as PAS and PABA, on the folate pathway of live Mycobacterium tuberculosis. It seems the bacterium is better at inactivating sulfonamides than PAS and that PAS does not really compete with PABA. Instead, PAS cascades through the folate pathway generating a series of poisonous intermediates.